Biotech Values

[DewDiligence]

Botulinum toxin update from MNT:

http://biz.yahoo.com/bw/070516/20070516006193.html?.v=1

>>
Mentor completed Phase I and Phase II clinical studies for the cosmetic indication for its botulinum toxin type A during fiscal 2007. On May 15th, Mentor received protocol approval from the FDA for its pivotal Phase III clinical trial and anticipates initiation of the study during the first fiscal quarter. [This sounds like they have an SPA but that’s not clear because they do not say so explicitly.] In an effort to accelerate the patient enrollment process in its therapeutic study, the Company has expanded the number of clinical sites in the dose escalation study focused on the treatment of pain associated with adult onset spasmodic torticollis/cervical dystonia.
<<

For some reason, MNT has dropped the product name, PureTox, from recent PR’s; I find this odd because I thought it was a good name. More important, I think this product is the first real threat to AGN’s blockbuster Botox franchise.